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Assessment of bone mass, ident(jication (?ifi"actllre risk, and determination (~r who should be treated 
~ are the optimal goals when evaluating patients for osteoporosis. 
"It's time, once again, for my annual checkup." Most 
women understand that this involves a cervical PAP smear 
and possibly a mammogram. However, few women think 
about their bones' health and consequently fail to give it 
its due importance. 
Peak bone mass is achieved by age 30. After that, as 
breakdown outstrips formation, bones slowly decrease in 
density. If the body is unable to maintain an adequate 
amount of bone formation, bones continue to lose density 
and become increasingly fragile, eventually resulting in 
osteoporosis. In women, the decrease in bone loss 
accelerates for five to ten years after menopause.] Thus, 
attention to skeletal health should be paid to prevent 
osteoporosis and consequently fractures. 
Osteoporosis 
Osteoporosis is a chronic condition of multifactorial 
aetiology and is usually clinically silent until a fracture 
occurs.2 It is the most common metabolic bone disorder 
and an increasingly significant problem, affecting 200 
million individuals worldwide.3 The World Health 
Organization estimated the prevalence of osteoporosis in 
western women at any site as 14.8% in women aged 50-
59,21.6% for ages 60-69, 38.5% for ages 70-79, rising 
to 70% in W0mt'n Clgt'ci RO 0r m0rt' 4 
In 1990, there were 1.7 million hip fractures worldwide. 
With changes in population demographics, this figure is 
expected to rise to 6 million by 2050.5 Often, osteoporosis 
is undertreated and underrecognized, in part because it is 
a clinically silent disease until it manifests in the form of 
fracture, most commonly of the hip, spine and wrist. As 
populations age, the number of osteoporotic fractures in 
elderly people will increase. Additional risk factors, such 
as urbanization, with the consequent increase in harder 
surfaces, will also result in greater number of fractures. s 
Risk Factors for Osteoporosis 
Osteoporosis can he primary or secondary. A female 
aged 60 years and over with a family history of osteoporosis 
has the highest risk for primary osteoporosis. A large risk 
factor study of 7782 women aged 65 years and older (with 
a mean age of 73.3 years) identified seven variables: 
• Age 
• BMD T-score 
• Fracture after age 50 years 
• A parental history of hip fracture especially maternal 
hip fracture after age 50 
• Smoking status 
• Thin body type with weight less than or equal to 57 kg 
or a low body mass index « 19) 
• Use of arms to get up from a chair.6 
Additional risk factors for osteoporosis include: 
• Early menopause (age <45) 
• Use of systemic corticosteroids 
• Excess alcohol intake 
• Hypogonadism 
• Physical inactivity.7 
Special attention must be given to patients suffering 
from other diseases or who are taking medications that 
might lead to secondary osteoporosis. Such diseases 
include Chronic renal failure, Cushing's disease, 
Hyperparathyroidism, Hyperthyroidism, Hypogonadism 
and Diabetes Mellitus. Corticosteroid use of 5 mg/day 
or more over 3 months, barbiturate and anticonvulsant 
therapy can all lead to secondary osteoporosis. 
Risk factors for low bone mass are not sufficiently sensitive 
for diagnosis or exclusion of osteoporosis. Only bone mineral 
density (BMD) measurement can identify patients who have a 
low bone mass.7 However, routine global BMD testing is cost-
prohibitive.8 Several decision rules have been developed to 
identify postmenopausal women who may be selected for dual-
energy x-ray absorptiometry (DEXA) scans for BMD 
measurements. One must look at the age of the patient as well 
as her weight and height to ~ilkulilt.t>; her HMI rBMJ less thiln 
19 predisposes to osteoporosis). Other risk factors should also 
be considered, especially family history of osteopomsis, smoking 
status and any low-trauma fractures. Studies9 have pmved that 
in younger postmenopausal women, such an appmach is useful 
to screen and assess the need for BMD scanning. 
Bone Mineral Density Scans 
DEXA scanning is today's established standard for 
measuring bone mineral density. It is also effective in 
tracking the effects of treatment for osteoporosis and 
other conditions that cause bone loss. It can assess an 
individual's risk for developing fractures. However, it 
cannot predict who will experience a fracture. 
Despite its effectiveness as a method of measuring bone 
density, DEXA is of limited use in people with a spinal 
deformity or those who have had previous spinal surgery. 
The presence of vertebral compression fractures or 
osteoarthritis may interfere with the accuracy of the test. 
The World Health Organization has used BMD to define 
specific diagnostic categories. It should be noted that all 
'normal' values of BMD are based on Caucasian data. 
The T-Score is a mathematical description of the deviancy 
of the individual from the mean of a reference population. 
AT-Score >-1 is normal. AT-Score -1 to -2.5 means 
osteopenia and aT-Score 2-2.5 means osteoporosis. 
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The Z-Score is an age-related score to identify patients 
whose bone mass is lower than that of individuals of the 
same age. A Z-Score ~1.5 means that there might be 
secondary causes for osteoporosis. 
Monitoring osteoporosis treatment using DEXA 
scanning is a controversial issue. Some doctors 
recommend DEXA scanning at 1 to 2 year intervals to 
monitor changes in bone density during treatment. In 
clinical practice, serial BMD measures have some 
clinical utility in monitoring response to therapy, but 
it is important to keep in mind that fracture -protection 
benefit may be realized before BMD gains are detected. 
If there is no change in BMD, it does not mean that the 
therapy is not working, because treatment may have 
prevented bone loss. 
Prevention and Treatment of Osteoporosis 
All patients should be advised to have a healthy, balanced 
diet rich in calcium and Vitamin D. Calcium is crucial for 
strong and healthy bones whilst vitamin D is important to 
help absorb calcium from food. The skin can usually make 
enough vitamin D when exposed to daylight. However, 
the use of sunblock creams prevents this effect of sunlight 
and it is now thought that many individuals are vitamin D 
deficient. Thus, individual patients may need calcium and 
vitamin D supplements. 
• A scanty guideline for patients would be that it is sensible 
to try to eat 3-4 portions of calcium a day. Milk, yogurt, 
cheese, nuts or seeds, bread, leafy green vegetables and 
fish with edible bones are all sources of calcium. 10 
• Eating a balanced diet with at least 5 portions of fruit 
and vegetables a day should enSUlfe that the patient gets 
enough ot other Important nutrients too. 
• Activities such as climbing stairs, brisk walking or 
dancing - known as 'weight-bearing' exercises - help 
make bones stronger. Doing these exercises for 30 
minutes , five days a week is ideal, but every little bit 
helps. Certain exercises also help the patient's balance, 
making it less likely for them to fall. 
• Smoking increases the risk of osteoporosis so the patient 
should be advised to quit if she smokes. 
• Sensible alcohol consumption doesn't seem to increase 
the chance of developing thin bones, but long-term heavy 
drinking might. 11 .12 For this and other reasons, it's not 
wise for women to drink more than 14 units of alcohol 
per week, with intake spread out over the whole week. 
Once osteoporosis is diagnosed, the goals of treating it 
are to prevent fractures, stabilize or achieve an increase 
in bone mass, relieve symptoms of fractures and skeletal 
deformity and maximize physical function. Treatment 
should include: 
1. Lifestyle and nutritional advice (as described before) 
2. Drug therapy 
3. Assessment and management of risk of falls, particularly 
in the elderly. 
According to the PRODIGY guidance, first-line treatment 
should include Alendronate (Fosamax®), Risendronate 
(Actonel®) or Ibandronate (Bonviva®). Strontium ranelate 
(Protelos®) is to be used as second-line treatment. However, 
there exists some controversy about this being used as 
first-line treatment. If the above fail, other treatments are 
available and these include Raloxifene (Evista®), 
Calcitonin, Cyclical Etidronate, Hormone Replacement 
Treatment and Teriparatide (Forsteo®).13 
Osteoporosis creates a huge socioeconomic burden of 
disease and disability. Identifying high-risk groups and 
using preventative treatment can result in a substantial 
reduction in morbidity and mortality. However, prevention 
should start early on in life, promoting increased calcium 
and vitamin D intake and daily regular weight-bearing 
exercise. Most women do not require a bone density 
examination till they reach the age of about 50 years, but 
this depends on the patient's risk factors. In the 
postmenopausal years, besides dietary advice, more emphasis 
should be given to screening for osteoporosis. 8J 
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